InvestorsHub Logo
Followers 20
Posts 1676
Boards Moderated 0
Alias Born 07/09/2005

Re: None

Thursday, 09/26/2019 2:32:51 PM

Thursday, September 26, 2019 2:32:51 PM

Post# of 768
06:38am 09/26/2019
AbbVie, Allergan rating change at Citi
Citi upgrades AbbVie to Buy, sees 'significant' value from Allergan deal. Citi analyst Andrew Baum upgraded AbbVie to Buy from Neutral and raised his price target for the shares to $90 from $87. The analyst believes AbbVie will "extract significant shareholder value" from Allergan's (AGN) franchises given its "strong commercial focus and patient/physician centricity." Further, within AbbVie's organic portfolio, Baum continues to think the market underappreciates the revenue potential.

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ABBV News